Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advancis Pulsatile Amoxicillin NDA Planned For 2005; Par Marketing To Focus On Pediatrics

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III program in adults and children will test a once-daily, five-day regimen of oral amoxicillin PULSYS totaling 5 g of antibiotic vs. 10 days of twice-daily conventional amoxicillin totaling 17.5 g of drug.

You may also be interested in...



Par Planning Megace ES Launch In Summer 2005 With In-House Sales Force

Par is looking for a second product to detail with the 50-60 person force it is building for extra strength Megace. The company hopes to get an "approvable" letter for the product in April and begin detailing in July.

Par Planning Megace ES Launch In Summer 2005 With In-House Sales Force

Par is looking for a second product to detail with the 50-60 person force it is building for extra strength Megace. The company hopes to get an "approvable" letter for the product in April and begin detailing in July.

Lilly Sells Keflex Antibiotic To Advancis; Plans For Once-Daily Dosing Underway

Advancis will commence clinical trials with Keflex using proprietary Pulsys drug delivery technology. The company also has Pulsys agreements with GSK for Augmentin and with Par for amoxicillin.

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel